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The amino termini of polyomavirus T antigens contain LXCXE and J domains, which are necessary for binding and
inactivating the retinoblastoma family of tumor suppressors. Both of these motifs are found in the JC virus (JCV) early proteins
T9135, T9136, and T9165, leading to the suggestion that these recently discovered proteins complement the cell-cycle-deregulating
function of the JCV large T antigen (TAg). To investigate this hypothesis, the three JCV T9 proteins were produced in a
baculovirus expression system and purified by immunoaffinity chromatography. To facilitate purification, hybridomas that
secrete antibodies recognizing amino-terminal epitopes of JCV early proteins were produced. Potential interactions between
the early viral proteins and the cellular proteins pRB, p107, and p130 were investigated by incubating purified JCV TAg and
T9 proteins with extracts of MOLT-4 cells, a human T cell line. The four viral proteins preferentially bound hypophosphorylated
species of the cellular proteins and exhibited the highest binding affinity to p107 and the lowest affinity to pRB. TAg and T9165
bound more pRB and less p107 than did T9135 and T9136; T9165 also bound less p130 than the other three early proteins. Results
of these in vitro interactions were compared to those obtained in vivo using POJ cells, a transformed human glial cell line that
expresses JCV early proteins, relatively high levels of pRB and p107, and low levels of p130. Most of the pRB in POJ cells is
hyperphosphorylated, and only a fraction of the hypophosphorylated form(s) of pRB is bound by the viral proteins. In contrast,
only hypophosphorylated p130 is detected in the transformed cells, and most of this protein was found in complex with the
viral proteins. Finally, nearly all of the p107 in POJ cells is bound by the JCV proteins. © 2000 Academic Press
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JC virus (JCV), the etiologic agent of the fatal demyeli-
nating disease progressive multifocal leukoencephalop-
athy (PML; Padgett et al., 1976), is highly oncogenic in
rodents and primates (Walker et al., 1973; London et al.,
1978; Ohsumi et al., 1986) and has been found in asso-
ciation with certain human tumors (Carbone et al., 1997;
Barbanti-Brodano et al., 1998; Gallia et al., 1998; Khalili et
al., 1999; Laghi et al., 1999). This human polyomavirus is
closely related genetically to two other viruses in this
genus, the human virus BKV and the monkey virus SV40
(Frisque et al., 1984); however, each virus exhibits unique
biological features. Relative to BKV and SV40, and in
contrast to its pathogenic potential in vivo, JCV displays
highly restricted lytic and transforming phenotypes in
vitro (Chuke et al., 1986; Walker and Frisque, 1986; Bollag
et al., 1989; Haggerty et al., 1989; Trowbridge and Fris-
que, 1993).
The primate polyomavirus genomes encode two early
multifunctional proteins, large and small T antigen (TAg,
tAg), which regulate viral DNA replication (Li and Kelly,
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1651984; Stillman et al., 1985; Fanning, 1992) and induce
cellular transformation (Monier, 1986; Bikel et al., 1987),
and four late proteins, which are assembled into the viral
capsid (VP1, VP2, and VP3) or influence the assembly
process (LP1) (Margolskee and Nathans, 1983). Because
of the limited coding capacity of these genomes, the
viruses are highly dependent on the replication machin-
ery of their hosts. Extensive analysis of the SV40 TAg
indicates that it is the only viral protein required for both
replication of viral DNA and establishment of transfor-
mation in cell culture (reviewed in Fanning, 1992; Pipas,
1992). These activities are regulated in part by discrete
functional domains located within the amino-terminal
portion of TAg. These domains include sequences in-
volved in nuclear localization of TAg, transactivation of
viral and cellular promoters, binding to the viral replica-
tion origin, and binding to a number of cellular proteins,
including DNA polymerase a, the pRB family of tumor
uppressors, heat shock protein hsc70, and certain
asal transcription factors (reviewed in Pipas, 1992;
rodsky and Pipas, 1998). Phosphorylation of specific
erine and threonine residues influences TAg function,
nd modification of amino acids in the carboxy terminus
f the protein affects phosphorylation events in the
mino terminus (Scheidtmann et al., 1991a,b). Studies ofwo “truncated” forms of SV40 TAg, the TN136 TAg pep-
ide and the recently discovered 17kT protein, indicate
0042-6822/00 $35.00
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166 BOLLAG ET AL.that many of these functional domains lie entirely within
the amino-terminal 131 residues of TAg (Zerrahn et al.,
993; Srinivasan et al., 1997). TN136 encodes three in-
dependently acting transforming functions that involve
an adenovirus E1A conserved region 1 (cr1) motif be-
tween amino acids 9 and 19, a cr2 motif between amino
acids 101 and 118 that contains a binding domain
(LXCXE) for the pRB family of proteins (Figge et al., 1988),
and a J domain within the amino-terminal 82 residues
(Kelley and Landry, 1994). The latter motif is found in the
DnaJ family of molecular chaperones, which interacts
with the DnaK family of chaperones. The J domain of
SV40 TAg interacts with hsc70 and, in concert with the
LXCXE domain, facilitates release of members of the E2F
family of S-phase transcription factors from un- and un-
derphosphorylated [un(der)phosphorylated] forms of
pRB (Nevins, 1992; Zalvide et al., 1998). These interac-
tions are thought to contribute both to viral DNA replica-
tion and to cellular transformation (reviewed in Brodsky
and Pipas, 1998).
Recently, it was reported that BKV and SV40 TAgs
differ with respect to the function of their pRB-binding
domains (Harris et al., 1998). BKV TAg (like JCV TAg) is
expressed at lower levels than SV40 TAg in most cells. At
these low levels, BKV TAg does not detectably bind to
pRB family members, but it still induces a serum-inde-
pendent semitransformed phenotype in some cells and
causes a decrease in pRB family proteins (Harris et al.,
1996, 1998). In addition, even in the absence of detect-
able TAg–pRB interactions, BKV TAg induces active E2F
by a mechanism that requires the LXCXE and J domains
of TAg. It was concluded that, in addition to TAg–pRB
interactions, alternate cellular mechanisms exist to effect
release of E2F (Harris et al., 1998).
The polyomavirus TAgs and tAgs are translated from
mRNAs alternatively spliced from a single precursor
early RNA. In SV40 the two proteins share the first 82
amino acids, but have unique carboxy-terminal se-
quences. Recently, additional small viral proteins, also
originating from the translation of alternatively spliced
early mRNAs, have been detected in some polyomavi-
ruses. These include SV40 17kT (Zerrahn et al., 1993),
mouse polyomavirus tiny T (Riley et al., 1997), and three
JCV T9 (Bollag et al., 1989; Trowbridge and Frisque, 1995)
roteins. While tiny T and 17KT proteins are expressed at
ery low levels and tiny T has a half-life of just 20 min
Zerrahn et al., 1993; Riley et al., 1997), the JCV T9 pro-
eins, T9135, T9136, and T9165, are expressed at high levels in a
lytic infection, and the half-life of T9136 is similar to that of
CV TAg (Trowbridge and Frisque, 1995). Recent studies
ndicate that the T9 proteins are required for efficient JCV
eplication and may contribute to transforming activity as
ell (Trowbridge and Frisque, 1993, 1995). To pursue this
atter possibility, the present study explores the potential
f the three JCV T9 proteins to interact with members of
he pRB family of tumor suppressors.RESULTS
roduction of MAbs recognizing JCV T9 proteins
To investigate the cellular expression of JCV early
roteins and to find suitable antibodies for the prepara-
ion of immunoaffinity columns for T9 purification, a panel
f monoclonal antibodies (MAbs) that recognized
pitopes between amino acids 1 and 132 of JCV TAg was
enerated. Two female Balb/cByJ mice were immunized
y injections with purified JCV TAg, and their spleen cells
ere fused with Sp2/0-Ag14 myeloma cells (see Materi-
ls and Methods). Five hybridomas secreting antibodies
Ab 2001, 2003, 2023, 2024, and 2030, which recognized
he JCV T9 proteins, were cloned from single cells. These
ew MAbs, together with MAbs obtained previously (see
able 1), were used to immunoprecipitate JCV early pro-
eins from lysates of POJ cells (Mandl et al., 1987) (Fig. 1).
n addition to JCV TAg and tAg, POJ cells express readily
etectable levels of T9135 and T9136 and low levels of T9165.
One additional band migrating slightly faster than T9165
was detected in these cells (Fig. 1, lanes 5, 8, 10–14) and
likely represents an unidentified JCV-specific protein pre-
viously observed in extracts of JCV-infected primary hu-
man fetal glial (PHFG) cells (Trowbridge and Frisque,
1995). Table 1 summarizes data from Fig. 1 and data not
shown regarding the abilities of PAb 2001, 2003, 2023,
2024, and 2030 to recognize the early proteins of primate
polyomaviruses. All five of these MAbs belong to the
immunoglobulin (Ig)G1 class/subclass of immunoglobu-
lins, and each recognizes denatured early viral proteins
in a Western blot assay. PAb 2023 exhibited a distinct
binding pattern; it was the only MAb to bind SV40 TAg,
and it failed to bind the JCV and BKV tAgs.
All MAbs capable of immunoprecipitating the JCV T9
roteins (Table 1) were used to prepare immunoaffinity
olumns, which were then tested for suitability in protein
urification. Columns prepared with three of the MAbs
ere found unsuitable: T9 proteins bound inefficiently to
the PAb 2023 column, and they were eluted inefficiently
from the PAb 416 and PAb 962 columns. Of the remaining
columns, the one prepared with PAb 2001 yielded the
largest amounts of purified T9 proteins and was therefore
chosen for use in immunoaffinity chromatography.
Expression and purification of three JCV T9 proteins
To investigate the functions of the JCV T9 proteins,
efficient expression and purification systems were re-
quired. To express all three proteins we employed a
baculovirus system that we had used previously to purify
large amounts of biologically active JCV TAg (Bollag et
al., 1996). Recombinant baculoviruses encoding the T9
proteins were produced by excising full-length T9 cDNAs
from cytomegalovirus (CMV)-T9135, CMV-T9136, and CMV-T9165
constructs (Fig. 2). These cDNAs were then inserted into
pVL-JCT(int-), from which a 2507-np fragment encoding
Te
B
C
i
a
P
b
p
M
I
t
p
p
t
t
c
o
a
T
b
t
s
a
P
re JCV
i
W
167FOUR JCV EARLY PROTEINS BIND pRB, p107, AND p130JCV TAg had been removed, to generate the three trans-
fer vectors pVL-T9135, pVL-T9136, and pVL-T9165. Cotrans-
fections of Sf9 insect cells with modified, linear DNA
from Autographa californica nuclear polyhedrosis virus
(AcNPV) and one of the three transfer vectors yielded the
recombinant baculoviruses BJC-T9135, BJC-T9136, and BJC-
9165, which were isolated by plaque purification (Sum-
mers and Smith, 1987). JCV TAg, T9135, T9136, and T9165 were
xpressed by infecting Sf9 cells with BJC-T, BJC-T9135,
JC-T9136, or BJC-T9165 at a multiplicity of 10 to 20 PFU/cell.
ell lysates were prepared 42 h postinfection (p.i.), clar-
fied by centrifugation, and incubated with the appropri-
te immunoaffinity columns. JCV TAg was eluted from a
Ab 2000 column using high-pH triethylamine elution
uffer as described (Bollag et al., 1996), and the three T9
roteins were eluted from a PAb 2001 column using 3.5
MgCl2–Tris elution buffer at pH 7.0.
T
Interaction of 10 Monoclonal Antibod
PAbb
Ig class and
subclass
TAg
epitopesc
Denatured
viral proteins T
416 IgG2a 83–130 (S) 1 11
419 IgG2a 1–82 (S) 1 2
901 IgG2a 684–698 (S) 1 11
962 IgG2a 1–81 (J) 1 11
2000 IgG1 1–81 (J) 1 11
2001 IgG1 1–81 (J) 1 11
2003 IgG1 1–81 (J) 1 11
2023 IgG1 1–132e (J) 1 11
2024 IgG1 1–81 (J) 1 11
2030 IgG1 1–81 (J) 1 11
a Differing amounts of immunoprecipitated viral proteins detected on g
visible, faint, or absent, respectively.
b Results are included for the following polyomavirus monoclonal a
(Harlow et al., 1981), PAb 901 (Deckhut et al., 1991; Tevethia et al., 199
c Amino acid positions within the SV40 (S) and JCV (J) TAgs.
d More than one species of BKV T9 may be produced (Bollag et al.,
e A very faint band was detected on one of the blots at a position whe
the first 81 amino acids rather than within residues 82 to 132 of TAg.
FIG. 1. Recognition of JCV early proteins by MAbs raised again
mmunoprecipitated with 10 different MAbs (IP Abs), fractionated on aestern blotting using a mixture of PAb 2001 and PAb 962 (Western Abs). Pos
T9165, and TAg were included as markers in lanes 1–4, respectively. K, molecunteractions of T9 proteins with pRB
The amino-terminal 132 amino acids of JCV TAg and
he three T9 proteins are shared. This region of the
rimate polyomavirus TAgs contains a J domain and a
RB binding site (LXCXE) that participate in disrupting
he cell-cycle-regulating functions of the pRB family of
umor suppressor proteins (Sheng et al., 1997). Trun-
ated SV40 TAg peptides spanning this region exhibit
ncogenic activity when expressed in cultured cells or in
nimals (Srinivasan et al., 1997; Tevethia et al., 1997a, b).
hese findings suggest that the JCV T9 proteins might
ind pRB, p107, and p130 and thereby contribute to the
ransforming potential of this virus. To pursue this pos-
ibility, we first determined whether T9 proteins inter-
cted with pRB using a coimmunoprecipitation assay.
urified TAg, T9135, T9136, or T9165 (6 pmol each) was incu-
h JCV, BKV, and SV40 Early Proteinsa
JCV BKV SV40
T9135 T9136 T9165 T t T9
d T t
11 11 11 11 2 11 11 2
2 2 2 2 2 2 11 1
2 2 1 11 2 2 11 2
11 11 11 11 6 1 1 2
2 2 2 2 2 2 2 2
11 11 11 11 1 1 2 2
11 11 11 11 1 6 2 2
1 1 1 1 2 1 1 2
11 11 11 11 1 1 2 2
11 11 11 11 1 1 2 2
shown as 11, 1, 6, and 2, indicating bands that were strong, clearly
es (PAb), published previously: PAb 416 (Arthur et al., 1988), PAb 419
962 (Tevethia et al., 1992), and PAb 2000 (Bollag and Frisque, 1992).
nd data not shown).
tAg would be expected, indicating that this antibody might bind within
0 or JCV TAgs. Proteins (250 mg) extracted from POJ cells were
DS–polyacrylamide gel, transferred to nitrocellulose, and analyzed byABLE 1
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2), PAb
1989, ast SV4
15% Sitions of the viral proteins on the blot are indicated; purified T9135, T9136,
lar mass in thousands.
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168 BOLLAG ET AL.bated individually with extracts (25 mg of protein) of
MOLT-4 cells containing pRB for 1 h at 4°C. Protein
complexes were immunoprecipitated with PAb 962 or
a-pRB followed by the addition of Pansorbin, fractionated
by SDS–polyacrylamide gel electrophoresis (PAGE), and
transferred to nitrocellulose. The presence of pRB on the
membrane was detected by Western blotting using
a-pRB (Fig. 3). Potential interactions of the viral proteins
with pRB were investigated using three different immu-
noprecipitation conditions; e.g., reaction mixtures were
incubated without antibody to serve as a negative control
(lane 1), with PAb962 to detect complex formation (lane
2), or with a-pRB to serve as a positive control (lane 3).
FIG. 2. Construction of recombinant baculovirus-JCV T9 vectors.
The recombinant baculovirus pVL-JCT(Int2) (Bollag et al., 1996),
containing the intact JCV TAg coding region minus intron se-
quences, was cleaved with EcoRI and NcoI to yield two fragments.
The larger fragment included the baculovirus polyhedrin promoter
sequences and the 59 terminal 33 nucleotides (nts) of the TAg gene.
This fragment was ligated to a smaller fragment obtained from one
of three vectors (CMV-T9135, CMV-T9136, or CMV-T9165) by digestion with
EcoRI and NcoI. These three small fragments contained the T9135,
T9136, or T9165 coding sequences minus the two introns and the first 33
nts which they share with TAg. The resulting vectors, pVL-T9135,
VL-T9136, and pVL-T9165 (identified as pVL-T9 in the figure), contain the
ntire coding regions for T9135, T9136, and T9165, respectively, which are
positioned immediately downstream from the polyhedrin promoter.
Numbers represent nt positions in the JCV genome (Frisque et al.,
1984). SD and SA identify the T/T9 splice donor and splice acceptor
sites. The asterisk represents the nt position of each of three T9
splice acceptor sites (nt No. 2704, 2777, or 2918).ll four JCV proteins bound hypophosphorylated forms of
RB (compare lanes 2, 5, 8, and 11 with lanes 3, 6, 9, and2, respectively), and TAg exhibited the highest binding
ctivity. T9165 was consistently found to bind more pRB
than the other two T9 species.
Interactions of T9 proteins with p107
SV40 and JCV TAgs associate with a second member
of the retinoblastoma family of proteins, p107, through
their LXCXE sequence (Dyson et al., 1989). p107 is func-
tionally related to, but structurally and immunologically
distinct from, pRB; its growth-suppressing activity is cell
type specific (Zhu et al., 1993). To determine if the T9
proteins interact with p107, the same experimental de-
sign as outlined for pRB binding was employed. Because
the MOLT-4 cell extracts appeared to contain much less
p107 than pRB based upon our Western blot analysis,
more extract (250 mg of protein) was used in these
xperiments. In addition, only 1.5 pmol of each viral
rotein was added to the binding reactions to facilitate
etection of differences in binding efficiencies. Protein
omplexes were immunoprecipitated with PAb 962 or
a-p107, fractionated by SDS–PAGE, and transferred to
nitrocellulose. The cellular protein was detected by
Western blotting with a-p107 (Fig. 4). All four early viral
roteins were found to bind the cellular protein (lanes 2,
, 8, 11); however, T9135 and T9136 interacted with p107 more
fficiently than did either TAg or T9165. Only a single p107
and was detected on our gels; therefore, we were
nable to assess whether TAg and the T9 proteins pref-
rentially interacted with un(der)phosphorylated p107 as
eported for SV40 TAg (Dyson et al., 1989).
nteractions of T9 proteins with p130
Using the coimmunoprecipitation assay described
bove, we tested the ability of the JCV early proteins to
ind p130, the third member of the retinoblastoma family.
ue to the low levels of p130 detected in MOLT-4 cells
ompared to those of pRB and p107, a greater amount of
ell extract (460 mg of protein) was incubated with TAg
nd the T9 proteins (4.5 pmol). Protein complexes were
mmunoprecipitated with PAb 962 or a-p130, fractionated
y SDS–PAGE, and transferred to nitrocellulose. The cel-
ular protein was detected by Western blotting with
a-p130 (Fig. 5). As reported for SV40 TAg (Stubdal et al.,
1997), the JCV TAg and T9 proteins bound almost exclu-
sively to the hypophosphorylated form of p130 (Fig. 5;
compare lanes 2, 5, 8, and 11 with lanes 3, 6, 9, and 12,
respectively). Again, distinct differences in binding effi-
ciencies were noted; lesser amounts of p130 were co-
immunoprecipitated with T9165 than with TAg, T9135, or T9136.
The faster migrating cellular protein detected on this
Western blot is likely p107 (Fig. 5, lanes 2, 5, 8, 11), since
the a-p130 antibody has been reported to cross-react
with p107 (Stubdal et al., 1996).
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169FOUR JCV EARLY PROTEINS BIND pRB, p107, AND p130Relative binding affinities of T/T9 proteins to pRB,
p107, and p130 expressed in MOLT-4 cells
JCV TAg and T9 proteins bind to a number of cellular
proteins; therefore, the binding of each viral protein to
one specific cellular protein would be expected to be
influenced by its interactions with other proteins in a
mixture. To determine relative binding affinities of the
T/T9 proteins to pRB, p107, and p130, MOLT-4 cell ex-
tracts (300 mg protein) were incubated with purified TAg,
9135, T9136, or T9165 (3 pmol each), and the complexes were
mmunoprecipitated with PAb 962. In addition, cellular
roteins in the extracts were immunoprecipitated with
a-pRB, a-p107, or a-p130 in the absence of viral proteins
to serve as controls. Proteins were fractionated on three
identical gels by SDS–PAGE and transferred to nitrocel-
lulose. The three retinoblastoma family members were
detected by Western blotting of the membranes with
a-pRB, a-p107, or a-p130 (Fig. 6). Each of the viral pro-
FIG. 3. Binding of pRB by T9135, T9136, and T9165. Proteins (25 mg) extrac
mol), immunoprecipitated with a-pRB or PAb 962 (IP Abs), fractionated
ith a-pRB (Western Ab). The position of pRB on the blot is indicated.
sterisk. K, molecular mass in thousands.
FIG. 4. Binding of p107 by T9135, T9136, and T9165. Proteins (250 mg) extrac
pmol), immunoprecipitated with a-p107 or PAb 962 (IP Abs), fractionated
with a-p107 (Western Ab). The position of p107 on the blot is indicated. Ig heav
conjugate are denoted by the asterisk. K, molecular mass in thousands.teins bound only a small fraction of pRB present in the
extract (Fig. 6; compare lanes 2, 4, 6, and 8 with lane 9 in
the upper blot), and this subpopulation of pRB repre-
sented a hypophosphorylated form(s). TAg and T9165 ex-
ibited higher binding affinities to pRB than did T9135 and
9136. In contrast, the four viral proteins bound essentially
all of the p107 present in the extracts (Fig. 6; compare
lanes 2, 4, 6, and 8 with lane 10 in the middle blot).
Finally, each viral protein bound most of the hypophos-
phorylated form(s) of p130 present in the extracts (com-
pare lanes 2, 4, 6, and 8 with lane 11 in the lower blot),
but an association with the hyperphosphorylated form of
p130 was not observed. As noted above, a cellular pro-
tein predicted to be p107 was detected by Western blot-
ting with the a-p130 antibody (Fig. 6, lanes 2, 4, 6, 8, 10,
11). In addition, the presence of a band in lane 10 that
migrates with the hyperphosphorylated band of p130
suggests that a-p107, the antibody used in the immuno-
precipitation, also cross-reacts with p130.
MOLT-4 cells were incubated with purified JCV T and T9 proteins (6
–PAGE, transferred to nitrocellulose, and analyzed by Western blotting
y chains detected by the a-mouse–IgG conjugate are denoted by the
MOLT-4 cells were incubated with purified JCV T and T9 proteins (1.5
–PAGE, transferred to nitrocellulose, and analyzed by Western blottingted from
by SDS
Ig heavted from
by SDSy chains migrating in the protein front and detected by the a-rabbit–IgG
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170 BOLLAG ET AL.Expression of pRB, p107, and p130 in POJ
and PHFG cells
SV40 TAg alters the phosphorylation pattern and pro-
motes the degradation of p130 (Stubdal et al., 1996,
997), and a recent study by Howard et al. (1998) sug-
gests that JCV TAg might exhibit similar activities. To
extend these observations, we compared the expression
of pRB, p107, and p130 in normal PHFG cells to that in
POJ cells, a JCV-transformed PHFG cell line that consti-
FIG. 5. Binding of p130 by T9135, T9136, and T9165. Proteins (460 mg) extrac
pmol), immunoprecipitated with a-p130 or PAb 962 (IP Abs), fractionated
with a-p130 (Western Ab). The positions of p130 and coimmunopre
a-rabbit–IgG conjugate are denoted by the asterisk. K, molecular mas
FIG. 6. Competitive binding of pRB, p107, and p130 by T9135, T9136, and T9165
T and T9 proteins (3 pmol), immunoprecipitated with PAb 962, a-pRB, a-p10nalyzed by Western blotting with a-pRB (top), a-p107 (middle), and a-p130 (bottom
g heavy chains detected by the a-mouse or a-rabbit–IgG conjugates are denotetutively produces the five JCV early proteins. Extracts
were prepared from PHFG and POJ cells, and proteins
were immunoprecipitated using PAb 962, a-pRB, a-p107,
or a-p130, fractionated by SDS–PAGE, and transferred to
itrocellulose. The three tumor suppressor proteins were
etected by Western blotting with a-pRB (Fig. 7, lanes
1–6), a-p107 (Fig. 7, lanes 7–12), and a-p130 (Fig. 7, lanes
13–18). Expression of hyperphosphorylated and hypo-
phosphorylated forms of p130 was detected in the un-
MOLT-4 cells were incubated with purified JCV T and T9 proteins (4.5
–PAGE, transferred to nitrocellulose, and analyzed by Western blotting
d p107 on the blot are indicated. Ig heavy chains detected by the
usands.
s (300 mg) extracted from MOLT-4 cells were incubated with purified JCV
130 (IP Abs) fractionated by SDS–PAGE, transferred to nitrocellulose, andted from
by SDS. Protein
7, or a-pblot) (Western Abs). The positions of pRB, p107, and p130 are indicated.
d by the asterisk. K, molecular mass in thousands.
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171FOUR JCV EARLY PROTEINS BIND pRB, p107, AND p130transformed PHFG cells, whereas in POJ cells only hy-
pophosphorylated p130 was observed (Fig. 7, lanes 17,
18). In addition, most of the hypophosphorylated p130
present in the POJ cells was bound by the JCV early
proteins (compare lanes 15 and 17).
The effect that JCV early proteins had upon pRB and
p107 expression in POJ cells differed from that observed
for p130. While pRB was weakly expressed as only a
hypophosphorylated form in PHFG cells, at least three
abundant forms of pRB were produced in POJ cells: a
hyperphosphorylated, a hypophosphorylated, and possi-
bly an unphosphorylated form of the protein (Fig. 7, lanes
5, 6). Only a small fraction of the un(der)phosphorylated
species was bound by the viral proteins (Fig. 7, lane 3).
JCV early protein expression also correlated with a large
increase in p107 expression in POJ cells relative to that
seen in PHFG cells (Fig. 7; compare lanes 11 and 12). In
contrast to our pRB observations, essentially all of the
p107 in POJ cells was complexed with the T/T9 proteins
Fig. 7; compare lanes 9 and 11).
DISCUSSION
Two objectives were pursued in this study: (i) to create
n expression and purification system for the production
f biologically active JCV T9 proteins and (ii) to investi-
ate potential interactions of these proteins with the pRB
amily of tumor suppressors. The JCV early region en-
odes five viral proteins, TAg, tAg, T9135, T9136, and T9165,
hich share their amino-terminal 81 amino acids. This
equence resembles the J domain of the DnaJ family of
FIG. 7. Expression of pRB, p107, and p130 in POJ and PHFG cells an
mg, lanes 13–18) extracted from POJ (P) or PHFG (G) cells were immunop
y SDS–PAGE the proteins were transferred to nitrocellulose. Cellular
(lanes 7–12), or a-p130 (lanes 13–18) (Western Abs). The positions of pR
protein front and detected by the a-mouse– or a-rabbit–IgG conjugateolecular chaperones (Cheetham et al., 1992; Kelley and
andry, 1994) and includes an E1A cr1 motif betweenmino acids 9 and 19, which is necessary for efficient
ellular transformation by SV40 (Srinivasan et al., 1997),
and an HPDKGG motif (J box) between amino acids 42
and 47, which is necessary for efficient SV40 DNA rep-
lication (Campbell et al., 1997). Through this latter motif,
SV40 TAg associates with hsc70 and stimulates its
ATPase activity (Sawai and Butel, 1989; Srinivasan et al.,
1997). The JCV TAg and three T9 proteins also share the
first 51 amino acids translated from their second exons,
which include the E1A cr2 motif LXCXE required for pRB
binding (Fig. 8). Both this latter sequence and an intact J
domain have been found in the case of SV40 TAg to be
necessary for the inactivation of the retinoblastoma fam-
ily of tumor suppressor proteins and for efficient trans-
formation (Stubdal et al., 1996, 1997; Zalvide et al., 1998).
In addition to the shared amino-terminal amino acids,
each T9 protein has a unique carboxy terminus; T9165
shares its 33 carboxy-terminal amino acids with those of
TAg, whereas T9135 and T9136 have unique carboxy termini
of 3 and 4 amino acids, respectively, which are translated
in a different reading frame (Fig. 8). The structures of the
three T9 proteins and their expression in transformed rat
and human cells (Fig. 2; Bollag et al., 1989; Haggerty et
al., 1989; Trowbridge and Frisque, 1993, 1995) support
the prediction that they complement the cell-cycle-dis-
rupting and transforming activities of TAg by binding to
pRB, p107, and p130. Furthermore, differences in the
carboxy termini of the JCV early proteins, which result in
altered phosphorylation patterns of individual T9 proteins
(Fig. 8), could indicate that expression and function of the
early viral proteins are regulated differently (Schneider
binding by the JCV early proteins. Proteins (360 mg, lanes 1–12; or 720
ated with PAb 962, a-pRB, a-p107, or a-p130 (IP Abs). After fractionating
s were detected by Western blotting with a-pRB (lanes 1–6), a-p107
7, and p130 on the blots are indicated. Ig heavy chains migrating in the
enoted by the asterisk. K, molecular mass in thousands.d their
recipit
proteinand Fanning, 1988; Scheidtmann et al., 1991a).
To accomplish our first objective, a baculovirus system
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172 BOLLAG ET AL.was chosen for the expression of each of the three T9
roteins. This method has been used to produce large
mounts of biologically active, posttranslationally modi-
ied proteins, including the JCV and SV40 TAgs (Lanford,
988; Murphy et al., 1988; Bollag et al., 1996). Sf9 insect
cells were infected with recombinant baculoviruses BJC-
T9135, BJC-T9136, and BJC-T9165, and T9 proteins were ex-
ressed in appreciable amounts; however, yields of pu-
ified proteins using the available immunoaffinity col-
mns were low. Therefore, new MAbs that recognize the
mino terminus of TAg were generated to identify re-
FIG. 8. Structural comparisons of JCV T9135, T9136, and T9165 with TAg. Am
amino acids 1 to 132 of TAg and include conserved region 1 (cr1; residu
identified in adenovirus E1A proteins, a J box (J; residues 42 to 47), and
of each T9 protein, which is encoded by exon No. 3, is unique. The carb
f TAg and includes a phosphorylation site at residue 161 (residue 68
omprising three and four amino acids, respectively, are translated in a
y the first exon of all early viral mRNAs is denoted by a dashed line, an
by a solid line. Numbers indicate positions of amino acids within TAg
included to maintain scale for the four viral proteins, which differ in sigents suitable for our purification scheme (Fig. 1).
hese antibodies should also prove useful in future stud-
p
ces, since they complement the small number of anti-JCV
Ag antibodies now available, and four of them, PAb
001, 2003, 2024, and 2030, discriminate between the
CV and SV40 TAgs (Table 1). All of the newly produced
Abs bound the three T9 proteins (Fig. 1) and were
ested for use in our immunoaffinity purification protocol.
owever, elution of T9 proteins from the immunoaffinity
olumns was inefficient when we used the high-pH
uffer that we had successfully employed earlier for TAg
urification (Bollag et al., 1996). It is possible that the
maller size or carboxy-terminal differences of the T9
ids encoded by the first two exons of all three T9 proteins overlap with
19) and conserved region 2 (cr2; residues 105 to 109), which are motifs
tential amino-terminal phosphorylation sites (P). The carboxy terminus
minus of T9165 (solid area) overlaps the 33 carboxy-terminal amino acids
g; Swenson and Frisque, 1995). The carboxy termini of T9135 and T9136,
t reading frame (hatched areas). The last amino acid (No. 81) encoded
st amino acid (No. 132) encoded by the second exon of the 3 T9 mRNAs
roken box between amino acids 132 and 655 of the TAg structure isino ac
es 9 to
four po
oxy ter
4 of TA
differen
d the laroteins relative to TAg account for their stronger asso-
iation with the antibody columns. Therefore the T9 pro-
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173FOUR JCV EARLY PROTEINS BIND pRB, p107, AND p130teins were eluted with a 3.5 M MgCl2 buffer at neutral pH,
resulting in the recovery of .95% of T9135, T9136, and T9165 in
the first 2.5 ml of eluant.
SV40 TAg binds pRB, p107, and p130 (DeCaprio et al.,
1988; Dyson et al., 1989; Ewen et al., 1989) and inacti-
ates their ability to inhibit cell cycle progression by
isrupting their interactions with members of the E2F
amily of transcription factors (Sheng et al., 1997; Stubdal
t al., 1997; Zalvide et al., 1998). JCV TAg is also known to
nteract with, and alter the function of, the pRB family of
umor suppressor proteins (Dyson et al., 1989; Tavis et
al., 1994; Howard et al., 1998). In addition, the JCV early
protein common region (amino acids 1 to 81) can func-
tionally replace the J domain of the Escherichia coli DnaJ
molecular chaperone (Kelley and Georgopoulos, 1997),
and recent results indicate that JCV TAg binds hsc70
expressed in POJ cells (Bollag, Prins, and Frisque, un-
published data). To demonstrate the ability of the JCV T9
proteins to bind pRB, p107, and p130, purified viral pro-
teins were incubated with extracts of MOLT-4 cells and a
coimmunoprecipitation assay was employed (Figs. 3–5).
These experiments revealed differences between TAg
and the T9 proteins with regard to the efficiencies with
which they bound pRB, p107, and p130. Of the three T9
proteins, T9165 is most similar in sequence to TAg,
whereas T9135 and T9136 are more closely related to one
another. This relatedness appeared to correlate with the
efficiencies with which these proteins bound pRB and
p107. For example, TAg and T9165 bound pRB with higher
affinity (Fig. 3) and p107 with lower affinity (Fig. 4) than
did the two smaller T9 proteins. This correlation, how-
ever, was less apparent when interactions involving p130
were compared (Fig. 5).
To demonstrate interactions between the viral proteins
and p107 and p130, a 10- to 20-fold excess of MOLT-4
extract was used relative to that required to show bind-
ing to the more abundant pRB. To directly compare the
binding affinities of the JCV early proteins for each of the
three cellular proteins in the same extract, an intermedi-
ate amount of MOLT-4 extract was used, and the proteins
in each immunoprecipitated sample were divided
equally among three identical gels, separated by elec-
trophoresis, and transferred to nitrocellulose for Western
blot analysis (Fig. 6). Despite the apparent large excess
of pRB present in each sample, the JCV early proteins,
including TAg, predominantly bound to p107 and p130,
indicating that they have a lower affinity for pRB than for
the other two cellular proteins.
After it was established that purified JCV early proteins
bound the pRB family of tumor suppressors expressed in
MOLT-4 cells, it was important to examine the interac-
tions between these viral and cellular proteins under
conditions in which they were coexpressed in cells. For
this experiment, extracts from untransformed PHFG vs
JCV-transformed PHFG (POJ) cells were used to examine
these interactions, as well as to compare the expressionand phosphorylation status of the cellular proteins in the
presence or absence of the viral proteins (Fig. 7). The
results revealed that in the JCV-transformed cells, p130
expression was reduced and only un(der)phosphory-
lated species were present, whereas p107 and pRB ex-
pression was increased substantially and the latter pro-
tein was more highly modified. These findings indicate
that coexpression of the JCV early proteins led to effects
on p130 different from those on p107 and pRB in the
transformed cells. All three cellular proteins are un(der)
phosphorylated during G0 and G1 and phosphorylated in
and G2 (Ludlow et al., 1990; Knudsen and Wang, 1998).
ur findings of differential phosphorylation of pRB (we
ould not clearly distinguish between modified forms of
107 on our gels) and differential expression of pRB and
107 in PHFG vs POJ cells may reflect differences in cell
ycle status of the transformed POJ cell line relative to
hat of the untransformed primary glial cells (Stubdal et
l., 1996; Knudsen and Wang, 1998). On the other hand,
he reduced levels of p130 and the absence of modified
orms of this protein in POJ cells compared to those seen
n PHFG cells confirm previous studies in which the
V40 and JCV TAgs were proposed to inhibit phosphor-
lation of newly synthesized p130 and to promote its
egradation (Stubdal et al., 1997; Howard et al., 1998).
he results presented in Fig. 7 are also consistent with
hose obtained with purified JCV early proteins and the
OLT-4 extracts (Figs. 3–6); the viral proteins bound only
fraction of the un(der)phosphorylated form(s) of pRB,
ut bound nearly all of the p107 and most of the p130
resent in the transformed cells.
Recently we generated Rat2 cell lines that stably ex-
ress individual JCV T9 proteins (Kilpatrick and Frisque,
npublished data). Using extracts from these cells and
he coimmunoprecipitation assay, we demonstrated that
nteractions observed between purified JCV early pro-
eins and the pRB family members in vitro also occur in
ivo (data not shown). In addition, experiments compa-
able to those involving POJ and PHFG cells (Fig. 7) were
erformed by comparing the levels and phosphorylation
tatus of pRB, p107, or p130 in the parental Rat2 line and
he Rat2 lines expressing T9135, T9136, or T9165. Although the
human and rat cell systems differ in obvious ways (spe-
cies derivation, immortalization status, growth rate, num-
ber of viral proteins expressed), viral–cellular protein
interactions detected in both sets of cells were similar.
Importantly, expression of JCV early proteins in either
human or rat cells resulted in reduced levels of hyper-
phosphorylated p130 relative to those observed in pa-
rental cells (Fig. 7; data not shown). On the other hand,
the levels of pRB and p107 detected in cells in the
presence or absence of a JCV protein showed distinct
patterns in human vs rat cells. Whereas the slowly divid-
ing parental PHFG cells contained much lower levels of
pRB and p107 than did the POJ cells, parental Rat2 cells
produced both proteins at levels nearly equivalent to
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174 BOLLAG ET AL.those found in Rat2 cells expressing a JCV early protein
(Fig. 7; data not shown).
Numerous studies have compared the activities of the
primate polyomavirus early regions, and the following
conclusions have been reached: (1) The JCV, BKV, and
SV40 TAgs are highly homologous and share a number
of functional domains; a subset of these sequences,
including the J and LXCXE domains, is encoded by the
JCV T9 proteins (Frisque et al., 1984; Trowbridge and
Frisque, 1995). (2) The JCV and BKV TAgs are less effi-
cient than their SV40 counterpart in mediating viral DNA
replication and transformation (Chuke et al., 1986; Bollag
et al., 1989; Haggerty et al., 1989; Lynch and Frisque,
1991; Sock et al., 1993). (3) JCV and BKV TAgs bind the
pRB family of tumor suppressors less efficiently than
does SV40 TAg (Dyson et al., 1989, 1990; Tavis et al.,
1994; Harris et al., 1996). (4) One or more T9 proteins
contribute to JCV replication and transforming potential
(Trowbridge and Frisque, 1993, 1995; Prins and Frisque,
unpublished data). (5) Levels of T9 mRNAs vary in differ-
ent cell types, presumably due to differential splicing of
the early precursor mRNA (Trowbridge and Frisque,
1995; Jones and Frisque, unpublished data). (6) JCV, BKV,
and SV40 are highly oncogenic in certain animal models
and each has been associated with human tumors (Car-
bone et al., 1997; Barbanti-Brodano et al., 1998; Gallia et
al., 1998; Khalili et al., 1999; Laghi et al., 1999). We
propose that results presented in the current study are
relevant to these conclusions. Each of the JCV T9 pro-
teins interacts with members of the retinoblastoma tu-
mor suppressor family of proteins and is likely to con-
tribute to TAg’s ability to disrupt cell cycle regulation. The
ability to stimulate entry into the S phase would, in turn,
influence viral replication or transforming efficiency, de-
pending on the cell type infected. In addition, the ability
of the three T9 proteins to differentially bind pRB, p107,
and p130 and affect their expression suggests not only
that overlapping and unique functions of these three cell
cycle regulators might be altered, but also that the ac-
tivities of other cellular factors involved in cell cycle
progression and in cellular and viral DNA replication and
transcription might be influenced differently by each T9
protein. Given that these “truncated” T proteins differ in
their activities and in their abundance in different cell
types, we suggest that the T9 proteins not only contribute
to the lytic and transforming behavior of JCV in vitro, but
also influence the tissue tropism and the pathogenic and
oncogenic potential of this virus in vivo.
Finally, it should be noted that our present findings
may be relevant to the recent suggestion that the BKV
and SV40 TAgs differ in their interactions with pRB (Har-
ris et al., 1996, 1998). Previously we demonstrated that
BKV, like JCV, produces significant amounts of T9 proteins
in transformed cells (Bollag et al., 1989). Further, we have
discovered that transfection of rat fibroblasts with a JCV
TAg cDNA construct yielded cell lines expressing highlevels of T9136 but low levels of TAg (Kilpatrick and Frisque,
npublished data). Apparently the T9 donor/acceptor
plice sites still present in the TAg cDNA were efficiently
tilized. Importantly, a similar event may have occurred in
he aforementioned BKV experiments which used similar
pproaches to construct BKV TAg-expressing cell lines.
lthough BKV TAg-pRB interactions were not detected in
hese studies (Harris et al., 1996, 1998), the status of BKV
9 protein expression was not discussed. If substantial
mounts of the T9 proteins were produced in the cells,
hey may have bound and inactivated the pRB family
embers, thereby yielding a serum-independent semi-
ransformed phenotype and the release of active E2F.
uch a scenario would obviate the need to propose
lternate cellular mechanisms to explain the observed
ellular effects (Harris et al., 1998).
MATERIALS AND METHODS
ells and cell extracts
Sf9 insect cells derived from Spodoptera frugiperda
ere cultivated at 27 to 30°C as spinner cultures in
NM-FH medium (Mediatech, Inc., Herndon, VA; Hink,
970; Summers and Smith, 1987), supplemented with
0% fetal bovine serum (FBS) and 50 mg/ml gentamycin.
rimary human fetal glial cells were maintained in Dul-
ecco’s modified Eagle medium (DMEM) supplemented
ith 3% bovine calf serum (BCS). POJ cells (Mandl et al.,
987), transformed PHFG cells expressing JCV early pro-
eins, were propagated in DMEM supplemented with 2%
BS and 8% BCS. CBRBBT-R2 and CSRSST-R2 (Bollag et
l., 1989; Bollag and Frisque, 1992), cloned transformed
at2 cells expressing BKV and SV40 early proteins, re-
pectively, were propagated in DMEM containing 5%
BS. DME media contained penicillin G (100 units/ml)
nd streptomycin (100 mg/ml). MOLT-4 cells (ATCC CRL
582, American Type Culture Collection, Rockville, MD),
uman T cells derived from a patient with acute lympho-
lastic leukemia, were cultivated in Iscove’s modified
ulbecco’s medium supplemented with 10% FBS, 5 3
025 M b-mercaptoethanol, and 100 mg/ml kanamycin.
All mammalian cells were cultivated at 37°C in a humid-
ified atmosphere containing 5% (POJ and MOLT-4 cells)
or 10% (PHFG, CBRBBT, and CSRSST cells) CO2.
Prior to the preparation of extracts, cells were washed
wice with cold STE (150 mM NaCl; 20 mM Tris–HCl, pH
.2; 1 mM EDTA). POJ, PHFG, CSRSST, and CBRBBT cells
ere lysed in EBC buffer (50 mM Tris–HCl, pH 8.0; 120
M NaCl; 0.5% NP-40) containing protease inhibitors [10
mg/ml aprotinin, 10 mg/ml E-64, 1 mM pefabloc (Boehr-
inger Mannheim Corp., Indianapolis, IN), and 10 mg/ml
leupeptin (Sigma–Aldrich, St. Louis, MO)] for 20 min with
agitation at 4°C. MOLT-4 cells were lysed in EBC buffer
containing phosphatase inhibitors [25 mM b-glycero-
phosphate; 5 mM NaF; 1 mM NaVaO4 (Sigma); and 5 mM
EDTA] in addition to the protease inhibitors.
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175FOUR JCV EARLY PROTEINS BIND pRB, p107, AND p130Viral expression vectors
Construction of CMV-T9 vectors. PHFG cells were in-
ected with JCV (Mad1), and total RNA was isolated 21
ays p.i. using the GlassMAX RNA Microisolation Spin
artridge System (Gibco BRL Life Technologies, Grand
sland, NY). RNA was reverse transcribed using random
examers provided with the Superscript Preamplification
ystem for First Strand cDNA Synthesis (Gibco BRL Life
echnologies). The resultant cDNA served as a template
or PCR using 10 pmol each of primers T9 No. 1 (JCV nt
os. 2580–2602; 59-CCAGCTTTACTTAACAGTTGCAG-39)
nd RT–PCR P5 (JCV nt Nos. 5019–4993; 59-GCTAAAAT-
GACAAAGTGCTGAATAGG-39), the 103 synthesis
uffer provided with the kit, and 5 U Taq polymerase
Promega, Madison, WI). PCR products were cloned into
he pCRII vector of the TA Cloning Kit (Invitrogen, Carls-
ad, CA) and transfected into bacterial cells (One Shot
ompetent Cells, Invitrogen). Clones containing inserts
f the correct sizes (756 np for T9135, 615 np for T9136, and
542 np for T9165 cDNAs) were sequenced. The correct T9
cDNA clones were then digested with EcoRI, which
cleaves on either side of the PCR product in the multiple
cloning site of pCRII, to isolate the JCV T9 cDNAs. pCR3
(Invitrogen), a linear mammalian expression vector con-
taining a CMV promoter, was also digested with EcoRI.
The T9 cDNA sequences were inserted into this site to
create CMV-T9135, CMV-T9136, and CMV-T9165.
Construction of baculovirus-JCV T9 vectors pVL-T9135,
pVL-T9136, and pVL-T9165. The construct pVL-JCT(Int
2) (Bol-
ag et al., 1996) containing the JCV TAg coding se-
uences (intron removed) was cleaved with EcoRI and
coI to remove a 2507-np fragment of the TAg coding
egion. Clones CMV-T9135, CMV-T9136, and CMV-T9165, con-
taining the full-length cDNA sequences of JCV T9135, T9136,
and T9165, respectively, linked to the pCR3 vector, were
digested with EcoRI to separate the JCV coding se-
quences from the pCR3 vector sequences and then with
NcoI to remove 59 pCRII sequences and JCV sequences
(33 np) encoding the amino terminus of the early viral
proteins. The NcoI–EcoRI fragments of the T9 clones
were ligated with the EcoRI–NcoI vector/JCV sequences
of pVL-JCT(Int2) to create pVL-T9135, pVL-T9136, and pVL-T9165
(Fig. 2).
Viruses
Recombinant baculoviruses BJC-T9135, BJC-T9136, and
BJC-T9165 were created by transfecting 2 3 10
6 Sf9 cells in
0-mm dishes with 0.5 mg of BaculoGold DNA (Pharm-
ingen, San Diego, CA) and 5 mg of pVL-T9135, pVL-T9136, or
pVL-T9165 using the BaculoGold Transfection Kit (Pharmin-
gen). After 5 days, recombinant viruses were isolated
and plaque-purified (Summers and Smith, 1987). The
recombinant baculovirus B-JCT encodes JCV TAg and
was described previously (Bollag et al., 1996).
i
bMonoclonal antibodies and immunoaffinity columns
A series of MAbs was made by the Hybridoma and
Cell Culture Laboratory of the Penn State Biotechnology
Institute. Two female Balb/cByJ mice (Jackson Lab, Bar
Harbor, ME) were injected intraperitoneally (ip) three
times at 2-week intervals with 50 mg of purified JCV TAg.
Two weeks after the third ip injection the mice were
given a booster injection of 100 mg TAg intravenously.
fter 4 days the mice were killed and their spleen cells
used with Sp2/0-Ag14 myeloma cells (ATCC CRL 1581).
en days after the fusion, hybridoma supernatants were
creened by enzyme-linked immunosorbent assay using
CV TAg-coated wells.
Five hybridomas that produced antibodies that recog-
ized JCV T9135, T9136, and T9165 proteins were cloned from
single cells. The immunoglobulin class and subclass of
each antibody were determined using the Immuno-Type
Mouse Monoclonal Antibody Isotyping Kit (Sigma). Typ-
ing results were verified by Western blotting with
a-mouse IgG subclass-specific antibodies conjugated to
alkaline phosphatase (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA). MAbs were purified by incubating hy-
bridoma supernatants with protein G–Sepharose beads
(Amersham Pharmacia Biotech, Inc., Piscataway, NJ) for
2.5 h at room temperature with agitation. The beads were
washed with 200 ml 100 mM Tris–HCl, pH 8.0, and 150 ml
10 mM Tris–HCl, pH 8.0. Antibodies were eluted with 10
ml 100 mM glycine, pH 3.0, dialyzed into PBS and, after
addition of 0.02% NaN3, stored at 280°C.
Immunoaffinity columns were prepared at room tem-
perature according to the method proposed by Schnei-
der et al. (1982). Purified MAbs (5–10 mg), dialyzed into
sodium–borate buffer (100 mM boric acid, adjusted to pH
8.2 with NaOH), were added to a protein G–Sepharose
column (1 ml) and the beads were agitated for 30 to 60
min. The column was washed three times with 10 ml
sodium–borate buffer and two times with 10 ml trietha-
nolamine buffer [200 mM triethanolamine (Sigma), ad-
justed to pH 8.2 with HCl] and incubated with 20 mM
dimethyl pimelimidate dihydrochloride (Sigma) in 10 ml
triethanolamine buffer for 45 min with agitation. Subse-
quently the column was incubated with 20 mM ethanol-
amine in 10 ml triethanolamine buffer for 10 min with
agitation. The immunoaffinity column was washed three
times with PBS and stored at 4°C in PBS containing
0.02% NaN3.
Production and purification of JCV early proteins
Sf9 cells (1.2 3 108) were infected with recombinant
baculovirus B-JCT, B-JCT9135, B-JCT9136, or B-JCT9165 at a
ultiplicity of infection of 10 to 20 PFU per cell. T and T9
rotein extractions were performed according to Simanis
nd Lane (1985) and Murphy et al. (1988) with the follow-ng modifications: infected cells were washed in TD
uffer (25 mM Tris–HCl, pH 7.4; 136 mM NaCl; 5.7 mM
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176 BOLLAG ET AL.KCl; 0.7 mM Na2HPO4) 42 to 48 h p.i. and lysed with
gitation at 4°C for 30 min in HEPES lysis buffer [50 mM
EPES, pH 9.0; 0.5% NP-40; 1 mM dithiothreitol (DTT);
0% glycerol; 10 mg/ml leupeptin]. Sodium acetate (200
M) was then added, and the lysates were clarified by
entrifugation at 4°C in a bench-top microcentrifuge.
JCV TAg was purified as described previously (Bollag
t al., 1996) with the following modifications: the triethyl-
mine elution buffer had a pH of 11.3, and the protease
nhibitor, leupeptin, was added to the protein solution
fter dialysis. The protocol was modified further to purify
9135, T9136, and T9165. The Sf9 cell lysate containing T9 pro-
tein was preadsorbed to a protein G–Sepharose column
(1 ml) for 45 min and then incubated with a PAb 2001
immunoaffinity column for 2 h. The columns were
washed with 150 ml Tris/NP-40 wash buffer I (50 mM
Tris–HCl, pH 8.0; 500 mM NaCl; 1 mM EDTA; 1% NP-40;
10% glycerol; 1 mg/ml leupeptin) and with 100 ml Tris
wash buffer II (50 mM Tris–HCl, pH 8.0; 500 mM NaCl; 1
mM EDTA; 10% glycerol; 1 mg/ml leupeptin). T9135, T9136, or
T9165 was eluted from the immunoaffinity column with 5 ml
MgCl2–Tris elution buffer (3.5 M MgCl2; 10% glycerol; pH
adjusted to 7.0 with 2 M Tris base). Protein-containing
fractions, as determined by the Bio-Rad protein microas-
say (Bio-Rad Laboratories, Hercules, CA), were com-
bined and dialyzed three times into T9-dialysis buffer (18
mM PIPES; 9 mM NaCl; 0.18 mM EDTA; 1.8 mM DTT; 10%
glycerol). After addition of 10 mg/ml leupeptin, the T9
solutions were concentrated to ;200 ml in Centricon 10
oncentrators (Amicon, Inc., Beverly, MA) by centrifuga-
ion at 5000g in a SM24 rotor at 4°C. Glycerol, containing
0 mg/ml leupeptin, was added to a final concentration of
50% to reconstitute protein storage buffer (10 mM PIPES,
pH 7.0; 5 mM NaCl; 0.1 mM EDTA; 1 mM DTT; 50%
glycerol). Concentrations of the T and T9 proteins were
determined by the Bio-Rad protein microassay and pro-
teins were stored at 220°C.
Antibodies used in immunoprecipitation and Western
blot assays
G3-245 (Pharmingen), a mouse IgG1 a-human pRB
MAb, is referred to here as a-pRB. p107(C-18) and
p130(C-20) (Santa Cruz Biotechnology, Inc.) are affinity-
purified rabbit polyclonal antibodies, each raised against
a peptide corresponding to the carboxy terminus of hu-
man p107 and p130, respectively. These antibodies are
referred to here as a-p107 and a-p130. The a-JCV TAg
Ab, PAb 962 (Tevethia et al., 1992), was purified from
edium in which the hybridoma was propagated. West-
rn blot reactions employing a-pRB and PAb 962 were
detected with a goat or rabbit a-mouse IgG conjugated
o alkaline phosphatase; those employing a-p107 anda-p130 were detected with a goat a-rabbit IgG conju-
gated to alkaline phosphatase (Sigma).
BImmunoprecipitation and Western blotting
MOLT-4 cell lysates were incubated with JCV T and T9
proteins for 60 min at 4°C with agitation. T and T9 pro-
teins were immunoprecipitated by incubation with PAb
962 and cellular proteins by incubation with a-pRB,
a-p107, or a-p130 for 45 min at 4°C with agitation. Im-
mune complexes were collected on fixed Staphylococ-
cus aureus cells (Pansorbin; Calbiochem-Novabiochem
Corp., La Jolla, CA), which in the case of IgG1 MAbs had
been treated with rabbit a-mouse IgG (Sigma) for 30 to
5 min at 4°C with agitation. Immune complexes bound
o Pansorbin were pelleted, washed once with EBC-
ased high-salt buffer (50 mM Tris–HCl, pH 8.0; 500 mM
aCl; 1% NP-40) and twice with EBC, suspended in 12 ml
f sample buffer (62.5 mM Tris–HCl; 10% glycerol; 2%
DS; 5% b-mercaptoethanol; 0.1% bromophenol blue; pH
.75), and heated at 95°C for 3 min. The proteins and
rotein standards (Multimark multicolored standards,
ovex; Rainbow colored protein molecular weight mark-
rs, Amersham Pharmacia Biotech) were separated on
DS–6% polyacrylamide gels and blotted onto nitrocel-
ulose membranes (Schleicher and Schuell, Keene, NH)
sing Hoeffer’s transfer buffer (25 mM Tris; 193 mM
lycine; 0.01% SDS; 20% methanol). The membranes
ere treated (5% nonfat dry milk; 0.1% Tween 20; 20 mM
ris–HCl; 137 mM NaCl; pH 7.6) to block nonspecific
inding and were incubated with the appropriate anti-
ody for 1 to 2 h at room temperature with agitation. After
xtensive washing, the membranes were incubated for 1
o 2 h at room temperature with a-mouse or a-rabbit IgG
onjugated to alkaline phosphatase. Proteins were visu-
lized by incubating each membrane for 5 to 20 min in 10
l of substrate solution buffer (100 mM Tris; 100 mM
aCl; 50 mM MgCl2; pH 9.5) containing 44 ml nitroblue
tetrazolium chloride and 33 ml 5-bromo-4-chloro-3-indolyl
hosphate p-toluidine salt (Immunoselect, Gibco BRL).
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